Register

Company Profile

Sourcing Inquiry Logo DiaTech Oncology

DiaTech Oncology

Regions
North America
Countries
Canada
Size
n.e.
Specialty
Biopharmaceuticals
Service category
Clinical development and testing, clinical CRO, Analytical laboratory and testing services
Content posted and uploaded by users. Want to add your company?
Your company? Get access to this profile.

Key services

Services

Clinical Services

  • Drug Sensitivity Testing
  • Leukemia and Lymphoma
  • Solid Tumor   
  • Diagnostic Multiparameter Flow Cytometry Analysis
  • Morphologic bone marrow, peripheral blood and body fluids evaluation
  • Morphologic evaluation for Non-Hodgkin's and Hodgkin's lymphomas and plasma cell neoplasm

Drug Sensitivity Testing

Microculture kinetic (MiCK) assay is used to identify chemotherapeutic agents that are the most effective in inducing apoptosis in tumor cells isolated from a specific patient. The MiCK assay is performed in a 96-well plate and allows testing sensitivity of the tumor cells to both single drugs and drug combinations. The referring physician may request testing sensitivity of the patient's tumor cells to specific chemotherapeutic agents or DiaTech may offer different panels of agents based on the patient's diagnosis and clinical history. Depending on the type of the specimen, testing results are available within 2-3 days (leukemia/lymphoma) or 3-4 days (solid tumors) after the specimen is received in the DiaTech laboratory.

Diagnostic multiparameter flow cytometry immunophenotyping can be performed on the specimen submitted for chemosensitivity studies if desired. DiaTech Oncology also offers flow cytometry immunophenotyping as an independent service. top of page

Leukemia and Lymphoma

The MiCK assay can be used to determine drug sensitivity of blasts isolated from patients with acute leukemias (AML and ALL), or blast phase of chronic myeloid leukemia (Kravtsov et al., 2000), and neoplastic cells of lymphoma patients. We also have experience in testing drug sensitivity of blasts isolated from patients with high-grade myelodysplastic syndrome (not published). It has been shown that acute myeloid leukemia patients whose treatment protocols included agents to which the patient's tumor cells were sensitive in the MiCK assay had increased rate of the complete remission (CR) and a significant advantage in long-term survival [Kravtsov et al., 1998; Kravtsov et al., 2001). In a limited study, the MiCK assay was successfully used to direct chemotherapy of patients with AML and blast phase of CML [Kravtsov et al., 2000]. Although there were no similar studies performed for lymphoma patients, the MiCK assay was demonstrated to detect drug-induced apoptosis in primary cultures of neoplastic cells from lymphoma patients. Using the MiCK assay, we may identify chemotherapeutic agents which are most effective in inducing apoptosis in lymphoma cells and, therefore, have the greatest probability to reduce tumor burden if included in the patient's treatment protocol. top of page

Solid Tumor

For research purposes, the MiCK assay was successfully used with cell lines originating from different types of solid tumors including colorectal carcinoma , bladder carcinoma, neuroblastoma,As part of the clinical services, drug sensitivity profiles were studied for tumor cells isolated from patients with advanced stages of breast, colon, lung, ovarian, prostate, and gastric carcinoma, visceral melanoma, soft tissue sarcoma, and carcinoma of unknown primary. Clinical trials to establish correlations between the MiCK assay results and treatment outcomes in patients with solid tumors are under way. For more information on the clinical trials, please go to http://www.clinicaltrials.gov/ct/show/NCT00243685 At present, DiaTech may identify chemotherapeutic agents which are the most effective in inducing apoptosis in tumor cells of a specific patient and, therefore, have the greatest probability to reduce tumor burden if included in the patient's treatment protocol. top of page

Diagnostic Multiparameter Flow Cytometry Analysis

DiaTech Oncology offers diagnostic multiparameter flow cytometry immunophenotyping service, which can be ordered on the specimens submitted for chemosensitivity testing or as an independent study. Four- or five-color flow cytometry immunophenotyping with comprehensive panels of antibodies is used to:

  • Make a diagnosis and assign cell lineage to leukemia and lymphoma
  • Detect a minimal residual involvement by leukemia and lymphoma after therapy

In some cases of non-hematopoietic malignancies, flow cytometry immunophenotyping is useful in detecting an expanded population of epithelial cells and, therefore, may serve as an accessory tool to morphologic studies.

Morphologic bone marrow, peripheral blood and body fluids evaluation

Morphologic bone marrow evaluation is performed on H&E-stained tissue sections and/or Wright-Giemsa stained bone marrow aspirate smears and/or touch preparations. Special stains including PAS, MPO, NSE, TRAP, GMS and others are used when clinically indicated upon verbal approval from the referring physician. Morphologic bone marrow evaluation can be ordered on the specimens submitted for chemosensitivity testing or as an independent study. If a malignancy is diagnosed, we inform the referring physician immediately by phone and generate a written report within 24h.

Peripheral blood smears are routinely examined with Wright-Giemsa stain. Special stains are added when clinically indicated upon verbal approval from the referring physician. Morphologic peripheral blood evaluation can be ordered on the specimens submitted for chemosensitivity testing or as an independent study. If a malignancy is diagnosed, we inform the referring physician immediately by phone and generate a written report within 24h.

CSF and other body fluids examination is performed on the Wright-Giemsa-stained cytospin preparations. A cytocentrifuge is utilized to concentrate cells from the body fluids to make morphologic evaluation more efficient.

Morphologic evaluation for Non-Hodgkin’s and Hodgkin’s lymphomas and plasma cell neoplasm

H&E stained sections of the lymph nodes and extranodal tissues are utilized to diagnose involvement by non-Hodgkin's or Hodgkin's lymphoma and plasma cell neoplasms. If a diagnosis of B- or T-cell non-Hodgkin's lymphoma is clinically suspected, chemosensitivity testing may be requested on the fresh specimen submitted for morphologic studies.

Special projects

You might be also interested in

Sourcing this company's services?

Send inquiry anonymously »

Or add this Company to
Sourcing cart